PriceTargets.com logo

Y-mAbs Therapeutics - YMAB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.89
  • Forecasted Upside: 152.28%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 2 Strong Buy Ratings
$8.28 As of 12/20/2024 06:17 PM ET
▼ -0.29 (-3.38%)

This chart shows the closing price for YMAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Y-mAbs Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for YMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for YMAB

Analyst Price Target is $20.89
▲ +152.28% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Y-mAbs Therapeutics in the last 3 months. The average price target is $20.89, with a high forecast of $26.00 and a low forecast of $11.00. The average price target represents a 152.28% upside from the last price of $8.28.

This chart shows the closing price for YMAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Y-mAbs Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/11/2024HC WainwrightReiterated RatingBuy ➝ Buy
12/5/2024Brookline Capital ManagementInitiated CoverageBuy$17.00
12/4/2024Brookline Capital ManagementUpgradeStrong-Buy
11/18/2024OppenheimerInitiated CoverageOutperform$23.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
9/10/2024WedbushReiterated RatingOutperform ➝ Outperform$23.00 ➝ $23.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00 ➝ $20.00
8/16/2024Cantor FitzgeraldInitiated CoverageOverweight$20.00
8/13/2024Canaccord Genuity GroupUpgradeStrong-Buy
8/13/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/13/2024Morgan StanleyLower TargetUnderweight ➝ Underweight$12.00 ➝ $11.00
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
8/13/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$26.00 ➝ $25.00
8/12/2024WedbushReiterated RatingOutperform$23.00
6/28/2024Truist FinancialInitiated CoverageBuy$21.00
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$21.00 ➝ $22.00
3/6/2024HC WainwrightBoost TargetBuy ➝ Buy$21.00 ➝ $22.00
3/4/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$22.00 ➝ $26.00
3/4/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$16.00 ➝ $26.00
2/20/2024HC WainwrightBoost TargetBuy ➝ Buy$11.00 ➝ $21.00
2/12/2024WedbushReiterated RatingOutperform$12.00 ➝ $18.00
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00
11/14/2023WedbushReiterated RatingOutperform$12.00
8/22/2023JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$8.00 ➝ $7.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00
8/14/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$7.00 ➝ $5.00
7/25/2023Canaccord Genuity GroupBoost TargetBuy$21.00 ➝ $22.00
5/15/2023Bank of AmericaBoost Target$6.00 ➝ $12.00
5/10/2023WedbushUpgradeNeutral ➝ Outperform$5.00 ➝ $13.00
4/4/2023HC WainwrightLower TargetBuy$19.00 ➝ $11.00
4/3/2023GuggenheimDowngradeBuy ➝ Neutral
3/31/2023Canaccord Genuity GroupLower TargetBuy$20.00 ➝ $18.00
1/30/2023BMO Capital MarketsBoost TargetOutperform$12.00 ➝ $13.00
1/27/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$4.00
1/5/2023CowenDowngradeOutperform ➝ Market Perform
1/5/2023CowenDowngradeOutperform ➝ Market Perform
12/5/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$23.00 ➝ $27.00
12/2/2022Bank of AmericaDowngradeBuy ➝ Neutral$23.00 ➝ $5.00
11/1/2022BMO Capital MarketsLower TargetOutperform$29.00 ➝ $12.00
10/31/2022Canaccord Genuity GroupLower Target$35.00 ➝ $27.00
10/31/2022Kempen & CoDowngradeBuy ➝ Neutral
10/31/2022Morgan StanleyLower TargetEqual Weight$17.00 ➝ $8.00
10/31/2022GuggenheimLower Target$26.00 ➝ $18.00
10/31/2022WedbushDowngradeOutperform ➝ Neutral$21.00 ➝ $6.00
10/31/2022HC WainwrightLower TargetBuy$63.00 ➝ $19.00
10/31/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$16.00 ➝ $7.00
9/9/2022Morgan StanleyBoost TargetEqual Weight$15.00 ➝ $17.00
6/23/2022BMO Capital MarketsInitiated CoverageOutperform$27.00
5/10/2022WedbushLower TargetOutperform$28.00 ➝ $21.00
4/29/2022HC WainwrightReiterated RatingBuy$63.00
4/28/2022WedbushLower Target$36.00 ➝ $28.00
2/28/2022HC WainwrightLower TargetBuy$68.00 ➝ $63.00
2/3/2022GuggenheimInitiated CoverageBuy$22.00
1/3/2022JPMorgan Chase & Co.Lower TargetNeutral$30.00 ➝ $27.00
12/22/2021HC WainwrightReiterated RatingBuy$68.00
11/19/2021Morgan StanleyInitiated CoverageEqual Weight$25.00
11/16/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$57.00 ➝ $30.00
10/8/2021HC WainwrightReiterated RatingBuy$68.00
9/14/2021HC WainwrightReiterated RatingBuy$68.00
8/9/2021HC WainwrightReiterated RatingBuy$68.00
7/7/2021HC WainwrightReiterated RatingBuy$68.00
6/28/2021HC WainwrightLower TargetBuy$70.00 ➝ $68.00
5/7/2021Bank of AmericaUpgradeNeutral ➝ Buy
4/21/2021WedbushLower TargetOutperform$67.00 ➝ $52.00
3/22/2021JPMorgan Chase & Co.Reiterated RatingOverweight$52.00
3/1/2021HC WainwrightBoost TargetBuy$65.00 ➝ $70.00
1/15/2021Bank of AmericaDowngradeBuy ➝ Neutral$56.00
12/17/2020WedbushBoost TargetOutperform$52.00 ➝ $71.00
12/17/2020BarclaysBoost TargetOverweight$55.00 ➝ $65.00
11/12/2020Morgan StanleyBoost TargetEqual Weight$42.00 ➝ $45.00
11/9/2020BarclaysBoost TargetPositive ➝ Overweight$47.00 ➝ $53.00
11/9/2020HC WainwrightBoost TargetBuy$52.00 ➝ $65.00
7/15/2020Morgan StanleyBoost TargetEqual Weight$39.00 ➝ $42.00
7/1/2020HC WainwrightReiterated RatingBuy$52.00
5/11/2020WedbushBoost TargetOutperform$41.00 ➝ $48.00
5/11/2020HC WainwrightBoost TargetBuy$41.00 ➝ $52.00
5/4/2020BarclaysInitiated CoverageOverweight$44.00
5/1/2020Janney Montgomery ScottInitiated CoverageBuy
4/29/2020Morgan StanleyInitiated CoverageEqual Weight
3/12/2020CowenReiterated RatingBuy
1/28/2020HC WainwrightReiterated RatingBuy$40.00 ➝ $41.00
12/24/2019JPMorgan Chase & Co.Initiated CoverageOverweight$39.00 ➝ $39.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 7 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 5 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 8 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 8 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Y-mAbs Therapeutics logo
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Read More

Today's Range

Now: $8.28
Low: $8.00
High: $8.50

50 Day Range

MA: $12.48
Low: $8.57
High: $15.69

52 Week Range

Now: $8.28
Low: $6.10
High: $20.90

Volume

1,143,018 shs

Average Volume

328,133 shs

Market Capitalization

$370.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Y-mAbs Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Y-mAbs Therapeutics in the last twelve months: BMO Capital Markets, Brookline Capital Management, Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, Morgan Stanley, Oppenheimer Holdings Inc., Truist Financial Co., and Wedbush.
View the latest analyst ratings for YMAB.

What is the current price target for Y-mAbs Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Y-mAbs Therapeutics in the last year. Their average twelve-month price target is $20.89, suggesting a possible upside of 152.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting YMAB will reach $26.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $11.00 for Y-mAbs Therapeutics in the next year.
View the latest price targets for YMAB.

What is the current consensus analyst rating for Y-mAbs Therapeutics?

Y-mAbs Therapeutics currently has 1 sell rating, 7 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe YMAB will outperform the market and that investors should add to their positions of Y-mAbs Therapeutics.
View the latest ratings for YMAB.

What other companies compete with Y-mAbs Therapeutics?

Other companies that are similar to Y-mAbs Therapeutics include Galapagos, Xencor, Evotec, Arcutis Biotherapeutics and Kiniksa Pharmaceuticals. Learn More about companies similar to Y-mAbs Therapeutics.

How do I contact Y-mAbs Therapeutics' investor relations team?

Y-mAbs Therapeutics' physical mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company's listed phone number is (646) 885-8505 and its investor relations email address is [email protected]. The official website for Y-mAbs Therapeutics is www.ymabs.com. Learn More about contacing Y-mAbs Therapeutics investor relations.